Biogen’s Aduhelm Competitors Boosted By Final CMS Coverage Decision
Eisai, Roche, Lilly Will Have Efficacy Data Much Sooner
The Center for Medicare and Medicaid Services’ final decision on Medicare coverage favors anti-amyloid antibodies approved for Alzheimer’s disease based on efficacy rather than biomarker data.
